We are live on
!
Find out more
MRCM
M&R Capital Management Portfolio holdings
AUM
$454M
1-Year Est. Return
40.11%
This Fund
S&P 500
This Quarter
Est. Return
+3.22%
1 Year Est. Return
+40.11%
3 Year Est. Return
+52.56%
5 Year Est. Return
+141.03%
10 Year Est. Return
+275.44%
AUM
$342M
AUM Growth
+$9.24M
(+2.8%)
Cap. Flow
+$40.9M
Cap. Flow
% of AUM
11.97%
Top 10 Holdings %
Top 10 Hldgs %
26.68%
Holding
578
New
393
Increased
86
Reduced
40
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class B
BRK.B
|
+$11.5M |
| 2 |
Johnson & Johnson
JNJ
|
+$5.54M |
| 3 |
CVS Health
CVS
|
+$5.52M |
| 4 |
IBM
IBM
|
+$4.63M |
| 5 |
ExxonMobil
XOM
|
+$4.07M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESRX
Express Scripts Holding Company
ESRX
|
+$8.16M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$4.33M |
| 3 |
MWR.CL
MORGAN STANLEY CAPITAL TRUST III
MWR.CL
|
+$4.18M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$2.14M |
| 5 |
Bausch Health
BHC
|
+$1.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 20.66% |
| 2 | Healthcare | 13.83% |
| 3 | Communication Services | 13.55% |
| 4 | Consumer Staples | 10.74% |
| 5 | Industrials | 10.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
GE Aerospace
GE
$355B
| $3.81M | 1.12% |
25,284
+846
| +3% | +$123K |
|
27
Sabesp
SBS
$17.1B
| $3.78M | 1.11% |
2,199,675
-43,526
| -2% | -$63.5K |
|
28
Pfizer
PFE
$159B
| $3.61M | 1.06% |
118,720
+11,973
| +11% | +$382K |
|
29
Colgate-Palmolive
CL
$72.3B
| $3.47M | 1.02% |
76,349
+26,129
| +52% | +$1.86M |
|
30
JPMorgan Chase
JPM
$951B
| $3.46M | 1.01% |
55,715
+20,944
| +60% | +$1.31M |
|
31
Henry Schein
HSIC
$9.98B
| $3.44M | 1.01% |
94,495
+45,917
| +95% | +$3.1M |
|
|
CSI
32
DELISTED
Cutwater Select Income Fund
CSI
| $3.44M | 1.01% |
173,650
-1,000
| -0.6% | -$19.3K |
|
33
Procter & Gamble
PG
$334B
| $3.44M | 1.01% |
57,304
+17,720
| +45% | +$1.45M |
|
34
Lloyds Banking Group
LYG
$85.7B
| $3.16M | 0.92% |
1,063,037
+33,722
| +3% | +$132K |
|
35
iShares Biotechnology ETF
IBB
$10.5B
| $3.02M | 0.88% |
35,181
+22,056
| +168% | +$1.98M |
|
36
BP
BP
$109B
| $2.8M | 0.82% |
93,816
+3,431
| +4% | +$92.4K |
|
37
Qualcomm
QCOM
$175B
| $2.8M | 0.82% |
52,205
-1,771
| -3% | -$93.3K |
|
|
38
IBM
IBM
$222B
| $2.77M | 0.81% |
50,654
+32,349
| +177% | +$4.63M |
|
|
39
Alphabet (Google) Class C
GOOG
$4.19T
| $2.69M | 0.79% |
77,900
-120,660
| -61% | -$4.33M |
|
40
State Street
STT
$53.1B
| $2.63M | 0.77% |
48,821
-1,839
| -4% | -$110K |
|
41
SLB Ltd
SLB
$85.1B
| $2.54M | 0.74% |
39,905
+8,498
| +27% | +$651K |
|
42
Verizon
VZ
$208B
| $2.47M | 0.72% |
44,293
+2,211
| +5% | +$115K |
|
43
Wells Fargo
WFC
$262B
| $2.47M | 0.72% |
52,143
+1,628
| +3% | +$79.4K |
|
44
Chevron
CVX
$396B
| $2.38M | 0.7% |
22,672
+434
| +2% | +$43.7K |
|
45
Waste Management
WM
$87.8B
| $2.16M | 0.63% |
32,535
-2,214
| -6% | -$134K |
|
46
Bristol-Myers Squibb
BMY
$136B
| $2.13M | 0.62% |
29,017
+75
| +0.3% | +$5.3K |
|
47
Merck
MRK
$366B
| $2.1M | 0.62% |
38,305
+254
| +0.7% | +$13.5K |
|
48
iShares Currency Hedged MSCI Eurozone ETF
HEZU
$597M
| $2.07M | 0.61% |
+86,110
| New | +$2.11M |
|
49
General Mills
GIS
$22.2B
| $1.97M | 0.58% |
27,623
+625
| +2% | +$39.8K |
|
50
AbbVie
ABBV
$451B
| $1.9M | 0.56% |
30,767
+2,178
| +8% | +$133K |
|
Similar funds
EDRIA
SFP
AC
NIC
WCA
KC
SIGI
FPFS
M&R Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, M&R Capital Management held 578 positions worth $342M, up 2.8% from $332M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
M&R Capital Management deployed $40.9M of net new capital in Q2 2016, opening 393 new positions and adding to 86 existing holdings. Its largest new stake was Berkshire Hathaway Class B: 80,680 shares worth $11.7M.
By sector, the portfolio is most concentrated in Financials at 21% of assets, up from 17% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was Express Scripts Holding Company, an estimated $8.16M trimmed.
- M&R Capital Management's largest Q2 2016 buy was Berkshire Hathaway Class B: 80,680 shares worth $11.7M.
- M&R Capital Management added most to Johnson & Johnson in Q2 2016, an estimated $5.54M increase.
- M&R Capital Management's biggest Q2 2016 reduction was Express Scripts Holding Company, cutting an estimated $8.16M.
- M&R Capital Management fully exited MORGAN STANLEY CAPITAL TRUST III in Q2 2016, selling an estimated $4.18M.
- M&R Capital Management's ten largest holdings make up 27% of its $342M portfolio in Q2 2016.
- M&R Capital Management opened 393 new positions and closed 32 in Q2 2016.
- M&R Capital Management's portfolio value rose 2.8% quarter-over-quarter to $342M.
Based on M&R Capital Management's 13F filing for Q2 2016, filed 10 Aug 2016.